Bliss GVS Pharma Limited — Others, 02-07-2025: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Bliss GVS Pharma has announced a board meeting on upcoming dates to discuss the financial results for the quarter and half-year. Separately, the company received a Show Cause Notice from the Joint Commissioner of CGST and Central Excise regarding an IGST refund claim of Rs. 6.65 crore during FY 2018-19. The notice questions the legitimacy of the refund and potential penalties. The company is preparing its response and states there is currently no impact on its financials or operations. This development is important for shareholders as it relates to tax compliance and contingent liabilities.